首页> Clinical cancer research : an official journal of the American Association for Cancer Research> SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.

SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.

导出 OA

翻译打印收藏纠错

第一作者： Gunther,Boysen

第一单位： Institute of Cancer Research, London, United Kingdom.

作者： Gunther,Boysen ^[1] ; Daniel N,Rodrigues ^[1] ; Pasquale,Rescigno ^[2] ; George,Seed ^[1] ; David,Dolling ^[1] ; Ruth,Riisnaes ^[1] ; Mateus,Crespo ^[1] ; Zafeiris,Zafeiriou ^[2] ; Semini,Sumanasuriya ^[2] ; Diletta,Bianchini ^[2] ; Joanne,Hunt ^[2] ; Deirdre,Moloney ^[2] ; Raquel,Perez-Lopez ^[3] ; Nina,Tunariu ^[2] ; Susana,Miranda ^[1] ; Inês,Figueiredo ^[1] ; Ana,Ferreira ^[1] ; Rossitza,Christova ^[1] ; Veronica,Gil ^[1] ; Sara,Aziz ^[1] ; Claudia,Bertan ^[1] ; Flavia M,de Oliveira ^[1] ; Mark,Atkin ^[1] ; Matthew,Clarke ^[1] ; Jane,Goodall ^[1] ; Adam,Sharp ^[1] ; Theresa,MacDonald ^[4] ; Mark A,Rubin ^[5] ; Wei,Yuan ^[1] ; Christopher E,Barbieri ^[6] ; Suzanne,Carreira ^[1] ; Joaquin,Mateo ^[3] ; Johann S,de Bono ^[7]

作者单位： Institute of Cancer Research, London, United Kingdom. ^[1] Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom. ^[2] Vall D'Hebron Institute of Oncology, Barcelona, Spain. ^[3] Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.;Englander Institute for Precision Medicine, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, New York. ^[4] Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.;Englander Institute for Precision Medicine, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, New York.;Department of Biomedical Research, University of Bern, Bern, Switzerland. ^[5] Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.;Department of Urology, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, New York. ^[6] Institute of Cancer Research, London, United Kingdom. johann.de-bono@icr.ac.uk.;Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom. ^[7]